Claims for Patent: 8,575,146

Summary for Patent: 8,575,146

Title:	Pharmaceutical uses of staurosporine derivatives
Abstract:	This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a Staurosporine Derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above.
Inventor(s):	Coutre; Steven (Stanford, CA)
Assignee:	Novartis AG (Basel, CH)
Application Number:	10/560,669
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,575,146
Patent Claims:	1. A method of treating mastocytosis, which comprises administering a therapeutically effective amount of a compound of formula (VII) ##STR00006## or a pharmaceutically acceptable salt thereof, to a human patient suffering from mastocytosis, wherein the human patient ha KIT tyrosine kinase receptor with a D816V mutation. 2. A method according to claim 1, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the compound is not administered and this cycle being repeated for from 1 to several cycles. 3. A method according to claim 1, wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily. 4. A method according to claim 1, wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily. 5. A method according to claim 1, wherein the compound of formula VII is administered three times a day, for a total dose of 225 mg daily. 6. A method according to claim 1, wherein the compound of formula VII is administered orally. 7. A method according to claim 1, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion. 8. A method according to claim 1, wherein up to 125 mg per day of the compound of formula VII is administered. 9. A method according to claim 4, wherein the compound of formula VII is administered orally. 10. A method according to claim 9, wherein the compound of formula VII is administered as a microemulsion. 11. A method of treating mastocytosis with resistance to imatinib, which comprises administering a therapeutically effective amount of a compound of formula (VII) ##STR00007## or a pharmaceutically acceptable salt thereof, to a patient suffering from mastocytosis with resistance to imatinib and wherein the patient ha KIT tyrosine kinase receptor with a D816V mutation. 12. A method according to claim 11, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the compound is not administered and this cycle being repeated for from 1 to several cycles. 13. A method according to claim 11, wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily. 14. A method according to claim 11, wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily. 15. A method according to claim 11, wherein the compound of formula VII is administered orally. 16. A method according to claim 11, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion. 17. A method according to claim 11, wherein up to 125 mg per day of the compound of formula VII is administered. 18. A method according to claim 14, wherein the compound of formula VII is administered orally. 19. A method according to claim 18, wherein the compound of formula VII is administered as a microemulsion.